Description: This is an excerpt from the Actuarial Research Conference Proceedings published in 2024. It is sponsored by the Education and Research Section of the Society of Actuaries and provides informational and educational content without offering professional or financial advice. The publication is not endorsed by the Society of Actuaries, and the opinions expressed are those of the individual authors.

Description: ASM-SOA Joint Seminar

Description: This is the fall 2008 basic education catalog.

Description: Table of contents for ARCH 2014.1

Description: 2011 Living to 100 Monograph table of contents by session.

Description: SOA predictive analytics certificate program provides strong theoretical background and practical, hands-on experience that can be applied to decision making

Description: Many drugs, like the immunologic drugs used to treat inflammatory and oncologic conditions, are FDA-authorized to treat more than one condition. Given different conditions have varying clinical outcomes and costs, it is likely the same drug provides a range of value across multiple conditions. However, such drugs have traditionally had a single list price and corresponding payer net cost. Indication-based pricing and benefit design (IBPBD) is intended to address the variable clinical and economic value for the same drug across multiple treatment indications. As this trend continues to evolve, the determination of drug value by treatment indication will create risks and/or opportunities in pharmacy benefit design, ultimately impacting pharmacy PMPM forecasting and incurred costs. Learn from faculty as they: Provide the business context for IBPBD. Describe varying structural approaches. Discuss the market conditions that can motivate or demotivate payers. Explore operational barriers. Recommend a role for actuaries. To bring the discussion to life, a case study will be reviewed. By attending the session, you will be able to: • Describe the meaning of Indication-Based Drug Pricing and Benefit Design (IDPBD). • Understand the risks and opportunities with IBPBD. • Articulate the advantages and disadvantages of distinguishing the value of a drug by treatment indications.

Description: Table of contents for The Actuary Magazine - December 2004

Description: Highlights of the Marketing and Distribution Section's survey, conducted during early fall of 2007. Survey questions could be categorized into five areas. There was a group of questions that captured the demographics of who answered the survey and their overall awareness of our section and involvement with our section. From News Direct, January 2007, Issue No. 57.